Retatrutide: The Triple Agonist Reshaping the GLP-1 Landscape

Retatrutide is a once-weekly injectable peptide developed by Eli Lilly that activates three hormone receptors: GLP-1, GIP, and the glucagon receptor — a step beyond semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP). LDL reductions observed in trials (roughly 20%) are thought to reflect glucagon receptor activity on PCSK9-related cholesterol clearance, distinct from appetite and glycemic effects.

Headline efficacy has climbed at each development stage. Phase 2 (obesity, NEJM 2023): up to 24.2% average weight loss at 48 weeks on the highest (12 mg) dose in participants without diabetes; in type 2 diabetes, 16.9% at 36 weeks with meaningful HbA1c improvement. TRIUMPH-4 (obesity with knee osteoarthritis, published December 2025): 28.7% average loss at 68 weeks on 12 mg. TRANSCEND-T2D-1 (type 2 diabetes, phase 3, published March 2026): HbA1c reduced by up to 1.94% from baseline 7.9% (vs 0.81% placebo), dose-dependent across 4 mg, 9 mg, and 12 mg arms; 12 mg arm also lost 16.8% body weight at 40 weeks.

• TRIUMPH-1 (obesity without diabetes, topline May 2026, 80 weeks, n=2,339): 4 mg → 17.6% loss; 9 mg → 23.7%; 12 mg → 25.0% (up to ~28.3% in some analyses); placebo → 3.9%
• In BMI ≥35 participants escalated to maximum tolerated dose for an additional 24 weeks, loss reached up to ~30%
• TRIUMPH-2 (obesity + type 2 diabetes) and TRIUMPH-3 (obesity + established cardiovascular disease) expected later in 2026

Tolerability tracks other incretin therapies, with GI effects dominating. Nausea, vomiting, diarrhea, and constipation are dose-dependent; phase 2 nausea ranged from ~14% at low doses to ~60% at 12 mg, often worst during escalation. Lower starting doses and gradual titration reduce severity.

• Heart rate: dose-dependent increase of roughly 5–10 bpm, often peaking around week 24 — monitor if you have cardiovascular concerns
• Dysesthesia (altered skin sensation): more specific to retatrutide than single-agonist GLP-1 drugs; ~1 in 5 at 9–12 mg in phase 3, usually mild; often resolves after discontinuation
• Serious adverse events: relatively rare in phase 2 (~4% vs placebo); pancreatitis, gallbladder issues, and liver enzyme elevation remain class risks warranting medical monitoring
• Long-term safety beyond ~1–2 years is still being established as TRIUMPH continues

A scoping review raised whether GLP-1 receptor agonists — including retatrutide — could theoretically reduce autologous fat graft survival via adipocyte browning, lipolysis, and altered adipose stem-cell differentiation. Retatrutide's glucagon activity was flagged as a particular mechanistic concern. No direct clinical studies in patients on these medications have confirmed graft outcomes; this remains hypothesis-generating, but relevant if planning fat-transfer procedures while using incretin-class compounds.

As of mid-2026, retatrutide remains investigational — not approved by the FDA, EMA, or other regulators for any indication. Eli Lilly's TRIUMPH program (5,800+ participants) is expected to support a filing, with industry projections often placing FDA submission in late 2026 and potential approval in 2027–2028 pending remaining data and review. An expanded access (compassionate use) pathway exists for narrow, case-by-case serious-disease scenarios under the investigational name LY3437943 — not general availability.

Retatrutide is a mechanistic step beyond single- and dual-agonist GLP-1 therapies, with glucagon receptor activity targeting energy expenditure as well as appetite and glycemic control. Phase 3 weight-loss signals (up to ~28–30% in highest-dose, longest-duration cohorts) are among the largest reported for the class. Tolerability is broadly similar to existing GLP-1 drugs, with GI effects dominant and dysesthesia as a newer class-specific finding. It remains investigational, with full approval likely still a year or more away pending remaining TRIUMPH readouts. Part 2 covers trial dosing structure and clinical monitoring — see retatrutide-dosing-monitoring.